JP2014205701A5 - - Google Patents

Download PDF

Info

Publication number
JP2014205701A5
JP2014205701A5 JP2014129106A JP2014129106A JP2014205701A5 JP 2014205701 A5 JP2014205701 A5 JP 2014205701A5 JP 2014129106 A JP2014129106 A JP 2014129106A JP 2014129106 A JP2014129106 A JP 2014129106A JP 2014205701 A5 JP2014205701 A5 JP 2014205701A5
Authority
JP
Japan
Prior art keywords
composition
composition according
dosage form
solid dosage
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014129106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014205701A (ja
JP5995331B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014205701A publication Critical patent/JP2014205701A/ja
Publication of JP2014205701A5 publication Critical patent/JP2014205701A5/ja
Application granted granted Critical
Publication of JP5995331B2 publication Critical patent/JP5995331B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014129106A 2007-01-19 2014-06-24 安定なチアクミシン組成物 Active JP5995331B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88113707P 2007-01-19 2007-01-19
US60/881,137 2007-01-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009546419A Division JP5635266B2 (ja) 2007-01-19 2008-01-17 安定なチアクミシン組成物

Publications (3)

Publication Number Publication Date
JP2014205701A JP2014205701A (ja) 2014-10-30
JP2014205701A5 true JP2014205701A5 (enExample) 2015-07-16
JP5995331B2 JP5995331B2 (ja) 2016-09-21

Family

ID=39641896

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009546419A Active JP5635266B2 (ja) 2007-01-19 2008-01-17 安定なチアクミシン組成物
JP2014129106A Active JP5995331B2 (ja) 2007-01-19 2014-06-24 安定なチアクミシン組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009546419A Active JP5635266B2 (ja) 2007-01-19 2008-01-17 安定なチアクミシン組成物

Country Status (22)

Country Link
US (2) US20080176927A1 (enExample)
EP (1) EP2121716B1 (enExample)
JP (2) JP5635266B2 (enExample)
KR (1) KR101491729B1 (enExample)
CN (2) CN102015747A (enExample)
BR (1) BRPI0806713A8 (enExample)
CA (1) CA2676003C (enExample)
CY (1) CY1117237T1 (enExample)
DK (1) DK2121716T3 (enExample)
ES (1) ES2560669T3 (enExample)
HR (1) HRP20151438T1 (enExample)
HU (1) HUE028671T2 (enExample)
IL (1) IL199941A (enExample)
MX (1) MX2009007784A (enExample)
NZ (1) NZ578493A (enExample)
PL (1) PL2121716T3 (enExample)
PT (1) PT2121716E (enExample)
RU (1) RU2484829C2 (enExample)
SI (1) SI2121716T1 (enExample)
TW (1) TWI474820B (enExample)
WO (1) WO2008091518A1 (enExample)
ZA (1) ZA200905134B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
BR112012029259A8 (pt) * 2010-05-18 2021-03-23 Optimer Pharmaceuticals Inc tratamento de infecção por clostridium difficile em pacientes sob terapia de antibióticos
WO2011146624A2 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Methods of treating recurring bacterial infection
EP2575487B1 (en) * 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
MX2013009033A (es) * 2011-02-04 2013-09-06 Optimer Pharmaceuticals Inc Tratamiento de infecciones bacterianas.
ITMI20120560A1 (it) 2012-04-05 2013-10-06 Olon Spa Procedimento per la purificazione della tiacumicina b
JO3464B1 (ar) * 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
PT3139932T (pt) * 2014-05-09 2018-11-14 Astellas Pharma Europe Ltd Regime de tratamento para composto de tiacumicina
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物
CN112353774B (zh) * 2020-11-17 2022-08-23 浙江汇能生物股份有限公司 一种那西肽风味咀嚼片及其制备方法及其在犬魏氏梭菌病上的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05192094A (ja) * 1991-09-03 1993-08-03 Takeda Chem Ind Ltd 造粒組成物
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
AU2003251902B2 (en) * 2002-07-29 2008-03-06 Merck Sharp & Dohme Llc Tiacumicin production
US9211259B2 (en) * 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
EP1572164A2 (en) * 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
MX2007009196A (es) 2005-01-31 2009-02-25 Optimer Pharmaceuticals Inc Compuestos macrocilicos de 18 miembros y analogos de los mismos.

Similar Documents

Publication Publication Date Title
JP2014205701A5 (enExample)
JP2015078230A5 (enExample)
JP2010516677A5 (enExample)
JP2011068653A5 (enExample)
RU2017109139A (ru) Таблетки, содержащие большую дозу рукапариба
NZ711179A (en) Oral formulations of deferasirox
PH12017502326A1 (en) Orodispersible dosage unit containing an estetrol component
PE20161373A1 (es) Composiciones de liberacion retardada de linaclotida
JP2018162255A5 (enExample)
NZ720906A (en) Orally disintegrating solid dosage unit containing an estetrol component
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
JP2015038135A5 (enExample)
JP2012031147A5 (enExample)
RU2014143536A (ru) Фармацевтическая композиция, содержащая омелсартана медоксомил и розувастатин или его соль
JP2015511635A5 (enExample)
JP2015510916A5 (enExample)
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
SA517390550B1 (ar) وحدة جرعة قابلة للتفتت في الفم تتضمن مكون أستيترول
NZ628993A (en) Pharmaceutical formulations comprising ccr3 antagonists
CA2676003A1 (en) Compositions of stable tiacumicins
PH12014501408A1 (en) Immediate release multi unit pellet system
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
AR091621A1 (es) Formas de presentacion farmaceuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofen-carboxamida
MX374106B (es) Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina.
JP2013528213A5 (enExample)